Address: Wolvenhoek 10
5211 HH ‘s-Hertogenbosch
The Netherlands
Tel: +31 (0)73 6158080
PamGene is a biomarker company, focused on opening up new opportunities for the development of Personalized Medicine (pre-clinical, translational and clinical). Most of PamGene’s projects are in oncology and many of these involve medicines that inhibit or modulate cellular kinases and kinase pathways. Our collaborators apply our technologies for biomarker research in several other diseases and fields of expertise such as the Central Nervous System, the Cardiovascular area, Immunology and Obesity.
Three unique aspects of PamGene’s proprietary biomarker technology are:
The empowerment of a completely new way of translational biomarker development.
The emphasis on evidence-based medicine development by delivering and supporting scientific hypotheses: Understanding the on and off-target activities of a medicine is key.
Fully developed CE marked instrumentation for testing in the clinic is available. Testing in a CLIA certified laboratory can be organized.
Classic diagnostics determine the nature of a disease but give little or no information on how patients will respond to treatment. PamGene’s Matching Medicine approach ultimately aims to provide medical oncologists with valuable additional data to create the best plan for a particular patient, guiding the selection of likely responders, and avoiding non-responders experiencing unnecessary side effects and lost time.
Patient:drug response data, known as a PamGene Index (PamInDx) patient profile, have the potential to provide valuable predictive information to facilitate the matching of a medicine to a specific patient prior to drug administration. PamGene’s ambition is for Matching Medicines™ to become part of routine clinical practice.
In summary, our Matching Medicines technology and approach aims to:
Help stratify patients for clinical trials
Contribute to the often difficult treatment decisions that doctors have to make based on information from limited clinical trials
Select the right drug for the right patient in those cases where a choice of kinase inhibitors is available (e.g. in leukaemia such as CML)
Help avoid unnecessary treatment of patients with drugs, avoiding side effects and avoiding unnecessary costs to the healthcare system
The EMA’s Peter Arlett looks back on two years of the Accelerating Clinical Trials in the European Union (ACT EU) initiative which aims to improve the environment for clinical trials…
New methodology for the 2024 Access to Medicine Index promises a stronger attempt to quantify whether drugs, vaccines, and diagnostics are actually making it all the way to patients in…
Claudia Martínez, generic & biosimilar medicines programme manager at the Access to Medicine Foundation, draws from a recent AMF report to outline what more generics companies can be doing to…
As part of a wide-ranging conversation with PharmaBoardroom published earlier this month, European Medicines Agency (EMA) Executive Director Emer Cooke laid out four of the Agency’s core focus areas for…
In conversation at DIA Europe 2023 in Basel, European Medicines Agency Executive Director Emer Cooke looks back at the lessons EMA has taken from the COVID-19 pandemic response, outlines the…
The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this…
The latest news from the Dutch pharma, biotech and healthcare industries, including the bullish comments of Argenx CEO Tim Van Hauwermeiren following the successful launch of its Vyvgart product; cancer…
The European Medicines Agency (EMA), the EU body responsible for the evaluation of medicinal products for use within the European Union, concluded a vote on Monday evening in Brussels following…
Leo de Haan of Aurobindo discusses how to maintain a profitable business in times of rock-bottom generics prices in the Netherlands, the resulting second pillar of specialty products for the…
Despite lacking a national champion to bolster its innovative eco-system since the 2007 acquisition of Organon by Schering Plough, the Netherlands nevertheless still sits in fourth position on the 2015…
The Netherlands is clearly a fertile environment for its 2,200 life science and medtech companies. However, the Dutch ambition to be a frontrunner in new healthcare challenges also comprises an…
Sobi is a leading integrated biopharmaceutical company dedicated to developing innovative therapies and services to improve the lives of rare disease patients and their families. Karel Fol, the country manager…
See our Cookie Privacy Policy Here
